NCT01079819View on ClinicalTrials.gov

Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-708163

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Alzheimer's Disease
Interventions
DRUG

BMS-708163

Capsule, Oral, 50 mg, once daily, 1 Day

DRUG

BMS-708163

Capsule, Oral, 125 mg, once daily, 14 Days

DRUG

Placebo

Capsule, Oral, 0 mg, One daily, 1 Day

DRUG

Placebo

Capsule, Oral, 0 mg, One daily, 14 Day

Trial Locations (3)

90630

West Coast Clinical Trials, Llc, Cypress

91206

California Clinical Trials Medical Group, Glendale

07724

Iberica Clinical Research Center, Eatontown

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY